相似文献
1
Progress in corticotropin-releasing factor-1 antagonist development.
Drug Discov Today. 2010 May;15(9-10):371-83. doi: 10.1016/j.drudis.2010.02.011. Epub 2010 Mar 3.
2
Don't stress about CRF: assessing the translational failures of CRFantagonists.
Psychopharmacology (Berl). 2017 May;234(9-10):1467-1481. doi: 10.1007/s00213-017-4556-2. Epub 2017 Mar 7.
3
Corticotropin releasing factor receptor antagonists for major depressive disorder.
Expert Opin Investig Drugs. 2011 Apr;20(4):519-35. doi: 10.1517/13543784.2011.565330.
4
Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
CNS Drugs. 2006;20(11):887-96. doi: 10.2165/00023210-200620110-00002.
5
Small molecule antagonists of the corticotropin releasing factor (CRF) receptor: recent medicinal chemistry developments.
Curr Top Med Chem. 2008;8(6):506-20. doi: 10.2174/156802608783955665.
6
Structure and Function of Small Non-Peptide CRF Antagonists and their Potential Clinical Use.
Curr Mol Pharmacol. 2017;10(4):270-281. doi: 10.2174/1874467209666161101144155.
7
Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.
Pharmacol Ther. 2010 Dec;128(3):460-87. doi: 10.1016/j.pharmthera.2010.08.011. Epub 2010 Sep 6.
8
Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Biochemistry. 2004 Apr 6;43(13):3996-4011. doi: 10.1021/bi036110a.
9
CRF receptors as a potential target in the development of novel pharmacotherapies for depression.
Curr Pharm Des. 2009;15(14):1587-94. doi: 10.2174/138161209788168083.
10
Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
Life Sci. 2006 Jan 25;78(9):909-19. doi: 10.1016/j.lfs.2005.06.003. Epub 2005 Aug 24.
引用本文的文献
1
Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research.
Mol Psychiatry. 2025 Jul 3. doi: 10.1038/s41380-025-03085-y.
2
Disruption of the CRF receptor eliminates morphine-induced sociability deficits and firing of oxytocinergic neurons in male mice.
Elife. 2025 Feb 5;13:RP100849. doi: 10.7554/eLife.100849.
3
Peripubertal antagonism of corticotropin-releasing factor receptor 1 results in sustained changes in behavioral plasticity and the transcriptomic profile of the amygdala.
Neuroscience. 2025 Feb 16;567:261-270. doi: 10.1016/j.neuroscience.2025.01.007. Epub 2025 Jan 9.
4
Peripubertal antagonism of corticotropin-releasing factor receptor 1 results in sustained changes in behavioral plasticity and the transcriptomic profile of the amygdala.
bioRxiv. 2025 Jan 4:2024.08.14.607957. doi: 10.1101/2024.08.14.607957.
5
Design, Synthesis, and Biological Evaluations of Novel Thiazolo[4,5-d]pyrimidine Corticotropin Releasing Factor (CRF) Receptor Antagonists as Potential Treatments for Stress Related Disorders and Congenital Adrenal Hyperplasia (CAH).
Molecules. 2024 Aug 1;29(15):3647. doi: 10.3390/molecules29153647.
6
Structural and Functional Insights into CRF Peptides and Their Receptors.
Biology (Basel). 2024 Feb 13;13(2):120. doi: 10.3390/biology13020120.
7
Cortisol as a Target for Treating Mental Disorders: A Promising Avenue for Therapy.
Mini Rev Med Chem. 2024;24(6):588-600. doi: 10.2174/0113895575262104230928042150.
8
Synaptic Effects Induced by Alcohol.
Curr Top Behav Neurosci. 2023 Feb 11. doi: 10.1007/7854_2022_412.
9
The Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) System of the Central Amygdala Mediates the Detrimental Effects of Chronic Social Defeat Stress in Rats.
eNeuro. 2022 Sep 21;9(5). doi: 10.1523/ENEURO.0260-22.2022. Print 2022 Sep-Oct.
10
Corticotropin-Releasing Hormone: Biology and Therapeutic Opportunities.
Biology (Basel). 2022 Dec 8;11(12):1785. doi: 10.3390/biology11121785.
本文引用的文献
1
Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor.
Curr Opin Investig Drugs. 2010 Jan;11(1):63-71.
2
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
J Med Chem. 2009 May 14;52(9):3073-83. doi: 10.1021/jm9000242.
3
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
J Med Chem. 2009 May 14;52(9):3084-92. doi: 10.1021/jm900025h.
4
Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats.
Addict Biol. 2009 Apr;14(2):130-43. doi: 10.1111/j.1369-1600.2008.00142.x.
5
Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse.
Biol Psychiatry. 2009 Jul 15;66(2):110-7. doi: 10.1016/j.biopsych.2009.01.010. Epub 2009 Feb 12.
6
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
J Med Chem. 2008 Dec 11;51(23):7370-9. doi: 10.1021/jm800744m.
7
Dihydropyrrole[2,3-d]pyridine derivatives as novel corticotropin-releasing factor-1 antagonists: mapping of the receptor binding pocket by in silico docking studies.
J Med Chem. 2008 Nov 27;51(22):7273-86. doi: 10.1021/jm800743q.
8
Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the spotlight.
Annu Rev Physiol. 2009;71:219-39. doi: 10.1146/annurev.physiol.010908.163221.
9
2-Arylpyrimidines: novel CRF-1 receptor antagonists.
Bioorg Med Chem Lett. 2008 Aug 15;18(16):4486-90. doi: 10.1016/j.bmcl.2008.07.063. Epub 2008 Jul 18.
10
Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats.
Alcohol Clin Exp Res. 2008 Sep;32(9):1535-42. doi: 10.1111/j.1530-0277.2008.00745.x. Epub 2008 Jul 10.
Zotero 插件